Tracking Symptoms and Disease Progression
At a Glance
Myotilinopathy (LGMD1A) is a slow-progressing muscle disease that typically begins in adulthood, between ages 40 and 60. Initial symptoms often include distal weakness like foot drop and gait changes, eventually affecting proximal muscles, but total loss of walking is uncommon.
Because Myotilinopathy (the modern name for LGMD1A) is a rare condition, the way it shows up can vary significantly from person to person. However, most individuals follow a general pattern of slow, progressive muscle weakness that begins in adulthood [1][2].
When Do Symptoms Start?
For most people with MYOT mutations, symptoms begin in middle to late adulthood, typically between the ages of 40 and 60 [1][2]. However, there is a wide range; some individuals may notice the first signs in their late 20s, while others may not have significant symptoms until their 70s [3].
This “late onset” is one reason the disease was historically distinguished from other childhood-onset muscular dystrophies [1].
Where Weakness Begins
Unlike many other limb-girdle muscular dystrophies that start in the hips, Myotilinopathy often begins distally—meaning in the muscles furthest from the center of the body [3][4]. Researchers are still studying exactly why distal muscles are often affected first in this specific structural myopathy, but it is a well-documented hallmark of the disease.
- The “Feet First” Pattern: Many patients first notice difficulty with their gait (how they walk). You might find it hard to walk on your heels or toes, or you might experience “foot drop,” where your toes catch on the ground while walking [3][5].
- The “Limb-Girdle” Pattern: In other cases, the weakness starts proximally, affecting the “girdle” muscles of the hips and shoulders [3]. This can make it difficult to climb stairs, get up from a low chair, or lift your arms above your head.
Regardless of where it starts, the weakness usually spreads to include both proximal and distal muscles over time [3][6].
How the Disease Progresses
The hallmark of Myotilinopathy is its slow and steady progression [6].
- Gait Changes: As the lower leg and hip muscles weaken, your walking style may change to compensate. You might develop a “waddling” gait or need to lift your knees higher to avoid tripping [5][7].
- Hand and Arm Involvement: While the legs are usually affected first, the hands and forearms may eventually become weak. This can make fine motor tasks, like opening heavy jars or buttoning shirts, more challenging over the years [3].
- Balance and Stability: As both distal and proximal muscles weaken, maintaining balance can become more difficult, increasing the risk of falls [7][8].
A person in their 60s or 70s living with Myotilinopathy might use ankle braces or a cane to stay active, but total loss of walking ability is not the typical norm [6].
The Rule of Variability
One of the most important things to understand about Myotilinopathy is intrafamilial variability [2][9]. Even within the same family, two people with the exact same genetic mutation may have very different experiences:
- One sibling might start with foot weakness at age 50.
- Another sibling might start with hip weakness at age 35.
- A third relative might carry the mutation but show almost no symptoms until very late in life [2].
This variability means your journey is unique. Your medical team will use tools like MRI imaging to track how your specific muscles are changing over time and adjust your care plan accordingly [10][11].
Common questions in this guide
At what age do Myotilinopathy symptoms usually start?
Where does muscle weakness begin in LGMD1A?
Will I eventually lose the ability to walk with Myotilinopathy?
Does Myotilinopathy affect everyone in the same family equally?
How will my doctor track my disease progression?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my specific MYOT mutation, is my weakness more likely to stay distal or eventually become proximal?
- 2.How often should we monitor my walking gait to see if I need assistive devices like braces?
- 3.Is the rate of progression I'm experiencing typical for Myotilinopathy, or should we look for other factors?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (11)
- 1
Myotilin gene duplication causing late-onset myotilinopathy.
Spinazzi M, Savarese M, Letournel F, et al.
European journal of neurology 2025; (32(1)):e70029 doi:10.1111/ene.70029.
PMID: 39757377 - 2
Homozygosity of the Dominant Myotilin c.179C>T (p.Ser60Phe) Mutation Causes a More Severe and Proximal Muscular Dystrophy.
Rudolf G, Suominen T, Penttilä S, et al.
Journal of neuromuscular diseases 2016; (3(2)):275-281 doi:10.3233/JND-150143.
PMID: 27854214 - 3
A novel in-frame deletion in MYOT causes an early adult onset distal myopathy.
Guglielmi V, Pancheri E, Cannone E, et al.
Clinical genetics 2023; (104(6)):705-710 doi:10.1111/cge.14413.
PMID: 37553249 - 4
Novel five nucleotide deletion in dysferlin leads to autosomal recessive limb-girdle muscular dystrophy.
Chen YL, Wu WB, Wang P, et al.
Physiological reports 2023; (11(24)):e15887 doi:10.14814/phy2.15887.
PMID: 38110300 - 5
Multisystem Myotilinopathy, including Myopathy and Left Ventricular Noncompaction, due to the MYOT Variant c.179C>T.
Finsterer J, Stöllberger C, Hasun M, et al.
Case reports in cardiology 2020; (2020()):5128069 doi:10.1155/2020/5128069.
PMID: 32509353 - 6
Natural History and Phenotypic Spectrum of Myofibrillar Myopathies and Myopathies Associated With MFM-Related Genes.
Wannarong T, Milone M, Selcen D, et al.
Neurology 2025; (105(10)):e214255 doi:10.1212/WNL.0000000000214255.
PMID: 41183253 - 7
Patterns of Clinical Progression Among Patients With Autosomal Recessive Limb-Girdle Muscular Dystrophy: A Systematic Review.
Cheung A, Audhya IF, Szabo SM, et al.
Journal of clinical neuromuscular disease 2023; (25(2)):65-80 doi:10.1097/CND.0000000000000461.
PMID: 37962193 - 8
Four Individuals with a Homozygous Mutation in Exon 1f of the PLEC Gene and Associated Myasthenic Features.
Mroczek M, Durmus H, Töpf A, et al.
Genes 2020; (11(7)) doi:10.3390/genes11070716.
PMID: 32605089 - 9
Dysferlinopathy in Tunisia: clinical spectrum, genetic background and prognostic profile.
Belhassen I, Laroussi S, Sakka S, et al.
Neuromuscular disorders : NMD 2023; (33(10)):718-727 doi:10.1016/j.nmd.2023.08.007.
PMID: 37716854 - 10
European muscle MRI study in limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A).
Barp A, Laforet P, Bello L, et al.
Journal of neurology 2020; (267(1)):45-56 doi:10.1007/s00415-019-09539-y.
PMID: 31555977 - 11
Classification of Muscular Dystrophies from MR Images Improves Using the Swin Transformer Deep Learning Model.
Mastropietro A, Casali N, Taccogna MG, et al.
Bioengineering (Basel, Switzerland) 2024; (11(6)) doi:10.3390/bioengineering11060580.
PMID: 38927816
This page explains Myotilinopathy (LGMD1A) symptoms and progression for educational purposes only. Always consult your neurologist or healthcare provider to monitor your specific condition and discuss care options.
Get notified when new evidence is published on Autosomal dominant limb-girdle muscular dystrophy type 1A.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.